Advertisement Pharmaceutical Business review - Page 5240 of 5291 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 25, 2026

FDA approves Lilly’s Onswik for type 2 diabetes in adults

The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for adults with type 2 diabetes (T2D).

The QWINT Phase III study enrolled more than 3,400 adults with type 2 diabetes across four registration studies. Credit: Andrzej Rostek/Shutterstock.com.